22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- China releases national human rights action plan for 2026-2030
- 7 people, 2 companies charged over deadly Hong Kong residential building fire
- Chinese researchers treat rare disease via new RNA editing technology
- Chinese scientists identify new midge species in SW China's Xizang
- China releases 150b aquatic juveniles during 2021-2025 to boost biodiversity
- China's anti-graft chief emphasizes high-quality development of anti-graft work
